Why RNAi-Based Oncology Must Move Beyond Single-Target Thinking

NUAgo Therapeutics CEO and Co-Founder, Robert Schickel, Ph.D., speaks with Advancing RNA about why RNAi-based oncology must move beyond single-target thinking, explaining that solid tumors behave as adaptive survival networks that demand silencing multiple genes at once.